- Hamburg, Germany-based Evotec (OTCPK:EVTCY) enters into a four-year research collaboration with Pfizer (NYSE:PFE) in the field of tissue fibrosis. Under the terms of the agreement, the companies will explore potential novel mechanisms as targeted anti-fibrotics in multi-organ fibrosis. Evotec will contribute its drug discovery platform and Pfizer will contribute key technologies, industrial scope and expertise in drug development and marketing.
- Specific financial terms are not disclosed but include an upfront payment to Evotec and development- and sales-based milestones.
- Evotec inked collaboration deals with Sanofi (NASDAQ:SNY) a month ago in the field of cancer immunotherapies and diabetes. The firms established a five-year drug discovery collaboration in March.
- Evotech consummated a drug discovery deal in Alzheimer's disease with Johnson & Johnson (NYSE:JNJ) in November 2013.